In defense of pharmacoepidemiology - Embracing the yin and yan of drug research

被引：128

作者：

Avorn, Jerry ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA

来源：

关键词：

D O I：

10.1056/NEJMp0706892

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2219 / 2221

页数：3

共 5 条

[1] Hormone replacement therapy, heart disease, and other considerations
Barrett-Connor, E
Grady, D
[J]. ANNUAL REVIEW OF PUBLIC HEALTH, 1998, 19 : 55 - 72
[2] HARRIS G, 2007, NY TIMES 0920
[3] MATHEWS AW, 2007, WALL STREET J 1105
[4] Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results
Schneeweiss, Sebastian
Patrick, Amanda R.
Sturmer, Til
Brookhart, M. Alan
Avorn, Jerry
Maclure, Malcolm
Rothman, Kenneth J.
Glynn, Robert J.
[J]. MEDICAL CARE, 2007, 45 (10) : S131 - S142
[5] Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J
Blauw, GJ
Murphy, MB
Bollen, ELEM
Buckley, BM
Cobbe, SM
Ford, I
Gaw, A
Hyland, M
Jukema, JW
Kamper, AM
Macfarlane, PW
Meinders, AE
Norrie, J
Packard, CJ
Perry, IJ
Stott, DJ
Sweeney, BJ
Twomey, C
Westendorp, RGJ
[J]. LANCET, 2002, 360 (9346) : 1623 - 1630